Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide and Rituximab in Elderly Frail DLBCL
NCT02955823Phase 2Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Sep 2016
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in diffuse large B-cell lymphoma (DLBCL), sponsored by Fondazione Italiana Linfomi. Primary endpoints: Overall Response Rate at 48 months and Clinical Relevant Toxicity at 48 months. Started Sep 2016; status: completed.
02
Drugs
lenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02955823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02955823.